Management of multidrug-resistant TB : novel treatments and their expansion to low resource settings
MetadataShow full item record
Despite overall progress in global TB control, the rising burden ofmultidrug-resistant TB (MDR-TB) threatens to undermine efforts to end theworldwide epidemic. Of the 27 countries classified as high burden for MDR-TB, 17 are in 'low' or 'low-middle' income countries. Shorter, all oral and less toxic multidrug combinations are required to improve treatment outcomes in these settings. Suitability for safe co-administration with HIV drugs is also desirable. A range of strategies and several new drugs (including bedaquiline, delamanid and linezolid) are currently undergoing advanced clinical evaluations to define their roles in achieving these aims. However, several clinical questions and logistical challenges need to be overcome before these new MDR-TB treatments fulfil their potential.
Sloan , D J & Lewis , J M 2016 , ' Management of multidrug-resistant TB : novel treatments and their expansion to low resource settings ' Transactions of the Royal Society of Tropical Medicine and Hygiene , vol 110 , no. 3 , trv107 , pp. 163-172 . DOI: 10.1093/trstmh/trv107
Transactions of the Royal Society of Tropical Medicine and Hygiene
© The Author 2016. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DescriptionThis article received no specific funding. JL is supported by the Wellcome Trust as a clinical PhD fellow [grant number 109105/Z/15/Z].
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.